EU Approves Novartis-Glaxo Deals

The drug giants won European Union regulatory approval for a complicated series of deals worth more than $20 billion that will focus Novartis’ scope and turn Glaxo into a vaccines-and-consumer-drug powerhouse.



from WSJ.com: US Business http://ift.tt/1z3MQ7N

via IFTTT